Overview
PSTV market data
Price History
PSTV price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$7.19 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.48 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.90 – $23.43 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $26.2 · P/B 17.62 · P/S 5.06.
Company news
Plus Therapeutics’ CNSide Diagnostics Signs Regional Agreement With Medical Mutual Covering ~1.2M People Throughout Ohio And Kentucky, To Provide CNSide Cerebrospinal Fluid Tumor Cell Enumeration AssayBenzinga · Jul 21, 2026, 11:35 AM
Plus Therapeutics Partners With Genomic Testing Cooperative To Integrate GTC's Next-Generation Sequencing Technology Into The CNSide Cerebrospinal Fluid Assay PlatformBenzinga · Jul 16, 2026, 11:37 AM
Plus Therapeutics Highlights Updated NCCN CNS Cancer Guidelines Reinforcing CSF Analysis In Leptomeningeal Metastases CareBenzinga · Jul 14, 2026, 11:34 AM
Plus Therapeutics Announces Name Change To Cerenome, With Nasdaq Trading Under Symbol 'CNSY,' Effective August 3; Reaffirms FY26 Milestone And Commercial GuidanceBenzinga · Jun 30, 2026, 11:40 AM
CNSide Diagnostics Strikes Deal With Elevance Health To Offer CNSide Cerebrospinal Fluid Tumor Cell Enumeration Assay, Effective May 1, 2026Benzinga · Jun 25, 2026, 11:40 AM
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For MondayBenzinga · Jun 8, 2026, 1:55 PM
8-K filing — PLUS THERAPEUTICS, INC. (PSTV)SEC EDGAR · Jun 5, 2026, 8:30 PM
Plus Therapeutics Subsidiary's Clinical Laboratory Gets Accreditation From College Of American PathologistsBenzinga · Jun 4, 2026, 11:35 AM
Plus Therapeutics Presents New Data On Health Economics Trial Evaluating Economic Impact Of Earlier Detection And Therapeutic Management Of LM Through CNSide Cerebrospinal Fluid AssayBenzinga · May 26, 2026, 11:35 AM
Plus Therapeutics Partners With Ephemeral Technologies To Deliver Unique AI Execution Platform For CNS OncologyBenzinga · May 19, 2026, 11:40 AM